Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

Core Viewpoint - UBS upgraded the rating of China Resources Mixc Lifestyle (01209) to "Buy" due to the company's superior ability to discover emerging brands compared to its peers, particularly in the context of the rise of domestic brands and the differentiation in brand performance [1] Group 1: Company Performance - The company is expected to benefit from signs of recovery in the domestic luxury retail market, which will support rental growth in existing malls [1] - The forecast for the company's earnings visibility from 2025 to 2027 is optimistic, with an expected annual compound growth rate of 15% [1] Group 2: Financial Metrics - The target price for the company has been raised from HKD 38 to HKD 48, reflecting the company's dividend payout ratio of 100%, including special dividends [1]